Ami Organics Ltd Share Price

Description

• The Company was initially formed as a partnership firm in the name of "Ami Organics" with effect from 03 January 2004 at Surat, India. The firm converted into a private limited company under the Companies Act, 1956 under the name of "Ami Organics Private Limited" with a certificate of incorporation dated 12 June 2007. Subsequently, the Company was converted into a public limited company, following which the Company`s name was changed to "Ami Organics Limited", and a fresh certificate of incorporation was issued by RoC on 18 April 2018. The company is one of the leading research and development (R&D) driven manufacturers of specialty chemicals with varied end usage, focussed towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals, especially from the recent acquisition of the business of Gujarat Organics Limited (GOL). As per the F&S Report, the company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. The Pharma Intermediates which the company manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, antiinflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant, commanding significant market share both in India and globally. The company`s Pharma Intermediates used for manufacturing of APIs and NCEs portfolio has expanded from over 425 products as of 31 March 2019, to over 450 products as of 31 March 2021. During the FY2021, Bonus shares were issued to the existing shareholders of the Company as on the record date of 31.03.2021 by issue of 2,10,00,000 Equity shares of face value of Rs. 10 each.The Bonus shares were allotted in the ratio of 2:1 i.e Two new equity shares for every one existing shares of the company. As on 31 March 2021,the company has one joint venture company,namely AMI Onco-Theranostics,LLC. During the month of September 2021,the company came out with an IPO which comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholders,mopped up a total of Rs 570 crore through its public issue.The company will utilise the proceeds from fresh issue and pre-IPO placement for repaying debts and meeting working capital requirements.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 14 September 2021.

• The Company was initially formed as a partnership firm in the name of "Ami Organics" with effect from 03 January 2004 at Surat, India. The firm converted into a private limited company under the Companies Act, 1956 under the name of "Ami Organics Private Limited" with a certificate of incorporation dated 12 June 2007. Subsequently, the Company was converted into a public limited company, following which the Company`s name was changed to "Ami Organics Limited", and a fresh certificate of incorporation was issued by RoC on 18 April 2018. The company is one of the leading research and development (R&D) driven manufacturers of specialty chemicals with varied end usage, focussed towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals, especially from the recent acquisition of the business of Gujarat Organics Limited (GOL). As per the F&S Report, the company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. The Pharma Intermediates which the company manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, antiinflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant, commanding significant market share both in India and globally. The company`s Pharma Intermediates used for manufacturing of APIs and NCEs portfolio has expanded from over 425 products as of 31 March 2019, to over 450 products as of 31 March 2021. During the FY2021, Bonus shares were issued to the existing shareholders of the Company as on the record date of 31.03.2021 by issue of 2,10,00,000 Equity shares of face value of Rs. 10 each.The Bonus shares were allotted in the ratio of 2:1 i.e Two new equity shares for every one existing shares of the company. As on 31 March 2021,the company has one joint venture company,namely AMI Onco-Theranostics,LLC. During the month of September 2021,the company came out with an IPO which comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholders,mopped up a total of Rs 570 crore through its public issue.The company will utilise the proceeds from fresh issue and pre-IPO placement for repaying debts and meeting working capital requirements.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India(NSE) on 14 September 2021.